Recall -- Firm Press Release FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company. Clinical Specialties Issues Voluntary Nationwide Recall of Avastin Unit Dose Syringes due to Potential Serious Eye Infection Contact:
Consumer:
Austin Gore
866-880-1915
 FOR IMMEDIATE RELEASE -March 18 , 2013 - Clinical Specialties is voluntarily recalling Avastin unit dose syringes.The product has or potentially could result in an infection within the eye. Clinical Specialties has received reports of five intra-ocular infections from physician’s office and this is how the problem was identified.This product was being used solely as an off label use by an ophthalmologist for macular degeneration and is packaged in sterile syringes. The affected product name lots are as follows:Lot Number Exp. Date Lot Number Exp. DateCABDAHAC:39 5/8/2013 CABDACAB:56 4/2/2013CABDAGAC:58 4/13/2013 CABDACAB:76 4/2/2013CABDAHAC:77 4/8/2013 CABDACAB:89 4/2/2013CABDBIAC:86 4/19/2013 CABDADAB:69 4/3/2013CABDCFAC:29 4/26/2013 CABDADAB:93 4/3/2013CABDAEAD:26 5/3/2013 CABDADAB:54 4/3/2013CABDAEAC:47 5/5/2013 CABDAEAB:96 4/4/2013CABDAEAC:58 5/5/2013 CABDAHAB:00 4/7/2013CABDAFAC:46 5/6/2013 CABDAHAB:59 4/7/2013CABDAIAC:46 5/9/2013 CABDAHAB:18 4/7/2013CABDBCAC:94 5/13/2013 CABDAJAB:30 4/9/2013CABDCCAC:26 5/23/2013 CABDAJAB:70 4/9/2013CABDCFAC:81 5/26/2013 CABDAJAB:97 4/9/2013CABDABAD:05 5/30/2013 CABDBAAB:63 4/10/2013CABDAFAC:47 5/6/2013 CABDBAAB:77 4/10/2013CABDAGAC:43 5/7/2013 CABDBAAB:54 4/10/2013CABDBDAC:69 5/14/2013 CABDBAAB:04 4/10/2013CABDBIAC:77 5/19/2013 CABDBEAB:97 4/14/2013CABDCHAC:19 5/28/2013 CABDBFAB:67 3/16/2013CABDAHAD:21 6/5/2013 CABDBFAB:61 4/15/2013CABDCFAC:17 5/26/2013 CABDBFAB:84 4/15/2013CABDAHAD:00 6/5/2013 CABDBGAB:34 4/16/2013CABDBCAC:47 5/13/2013 CABDBHAB:33 4/17/2013CABDCBAC:97 5/22/2013 CABDBHAB:71 4/17/2013CABDAGAC:08 5/7/2013 CABDBHAB:75 4/17/2013CABDBCAC:15 5/13/2013 CABDCBAB:66 4/21/2013CABDBDAC:17 5/14/2013 CABDCCAB:64 4/22/2013CABDCIAC:42 5/29/2013 CABDCDAB:38 4/23/2013CABDBEAC:44 5/15/2013 CABDCEAB:71 4/24/2013CABDCBAC:79 5/22/2013 CABDCEAB:04 4/24/2013CABDCIAC:00 5/29/2013 CABDCFAB:22 3/26/2013CABDAHAD:82 6/5/2013 CABDCFAB:14 4/25/2013CABDCBAC:31 5/22/2013 CABDCIAB:51 4/28/2013CABDCIAB:68 4/28/2013 CABDCIAB:93 3/29/2013CABDCJAB:59 4/29/2013 CABDDBAB:71 4/1/2013CABDDBAB:93 5/1/2013 CABCBJBC:00 3/19/2013CABCCGBC:92 2/24/2013 CABCCGBC:30 3/26/2013CABCCGBC:49 3/26/2013 CABCCHBC:55 3/27/2013CABCCIBC:39 3/23/2013 CABCDBBC:87 3/31/2013CABCDBBC:71 3/1/2013    This product would be administered by a licensed physician in a surgery or physician’s office setting. The syringes were distributed to doctors’ offices in Georgia, Louisiana, South Carolina, and Indiana from December 18, 2012 to present.Clinical Specialties has notified the physician’ offices by telephone. Doctors that have product which is being recalled should stop using the Avastin immediately.Consumers with questions regarding this recall may contact Clinical Specialties by phone at 866.880.1915 or e-mail address at This e-mail address is being protected from spambots. You need JavaScript enabled to view it ; Monday through Friday between the hours of 10 am to 5 pm EST. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Online: www.fda.gov/medwatch/report.htm

Regular Mail: use postage-paid, pre-addressed Form FDA 3500 available at:
www.fda.gov/MedWatch/getforms.htm. Mail to address on the pre-addressed form.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Fax: 1-800-FDA-0178

###

RSS Feed for FDA Recalls Information [what's this?]

    

-